



Xellia Pharmaceuticals globally certified as a Great Place to Work® following company-wide employee survey

Copenhagen, Denmark, 21 June 2021 - Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments, has been confirmed as an official recipient of the certification and recognition as a Great Place to Work® following a global company-wide employee survey conducted by [Great Place to Work®](#).

Xellia's employees from all sites across Europe, the US, the Middle East and Asia were invited to participate in the survey. A total of 90% of Xellia's employees participated, displaying high levels of engagement, as well as securing the validity of the survey results. The results of the survey demonstrated a very positive response when colleagues were asked if Xellia is a great place to work, taking all aspects into account. Furthermore, several key qualities were highlighted as positive employee experiences across the organization, namely; employees experience Xellia as an equal opportunity employer, demonstrating of a strong sense of fairness throughout the organization, a high level of camaraderie and pride in the workplace, and a display of strong values across the organization.

The organization Great Place to Work® specializes in workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used the insights gathered to define what makes a great workplace experience. Great Place to Work® helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees. Their benchmark data is used to recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in more than 60 countries worldwide, including those on the US 100 Best Companies to Work For® and World's Best lists published annually by Fortune.

Carl-Aake Carlsson, CEO at Xellia Pharmaceuticals, commented:

"Our certification as a 'Great Place to Work' is a fantastic reflection of the culture at Xellia, where we believe strongly that our people make us what we are. We thrive on a spirit of innovation, excellence and teamwork. Our leaders are building talented teams to reflect this, and an environment which supports empowerment and engagement. We are proud that so many of our employees feel safe, respected and welcome at Xellia."

Liselotte Jensen, Managing Director at Great Place to Work® in Denmark, stated:

"It's great to see such positive employee experiences in Xellia. It is quite an achievement to become Great Place to Work® certified in a company of this size and with the extensive global reach in first try. It demonstrates Xellia's commitment to creating a high-trust workplace and delivery on values - and with a purpose that are meaningful to its staff."

To learn more about working at Xellia see the global recruitment film on [Xellia's website](#).

If you are interested in joining the Xellia team, please visit the Company's career page at <https://career5.successfactors.eu/career?company=xelliapharma>.

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris/ Siobhan Sanford

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com. Connect with us on [LinkedIn](#).